Full Text
PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis

Abstract

Authors

A.R. Walker B. Deniz S.T. Alexopoulos R. Arnold D. Bates

Back to Volume 15, Issue 4
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×